Evolus, Inc. (EOLS)

Market Cap	885.87M
Revenue (ttm)	248.33M
Net Income (ttm)	-55.46M
Shares Out	63.32M
EPS (ttm)	-0.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	577,728
Open	14.78
Previous Close	14.62
Day's Range	13.80 - 14.78
52-Week Range	9.25 - 17.82
Beta	1.33
Analysts	Strong Buy
Price Target	23.80 (+70.12%)
Earnings Date	Mar 4, 2025

About EOLS

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 8, 2018
• Employees: 273
• Stock Exchange: NASDAQ
• Ticker Symbol: EOLS
• Website: https://www.evolus.com

Financial Performance

In 2023, Evolus's revenue was $202.09 million, an increase of 35.98% compared to the previous year's $148.62 million. Losses were -$61.69 million, -17.10% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price forecast is $23.8, which is an increase of 70.12% from the latest price.

Price Target

$23.8

(70.12% upside)

Analyst Consensus: Strong Buy